Immuneering Corporation — Q2 2021 Form 10-Q
Reporting period: Three and six months ended June 30, 2021; unaudited. Immuneering is an early-stage biopharmaceutical company developing oncology and neuroscience candidates and also earns revenue from computational biology services. It had not completed a clinical trial or received approval for a product at the filing date.
Financial results and liquidity
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | $0.66 million | $0.48 million | $1.41 million | $0.96 million |
| Gross profit | $0.34 million | $0.24 million | $0.68 million | $0.47 million |
| Gross margin | 51.7% | 50.7% | 48.3% | 48.9% |
| Research and development | $6.99 million | $3.22 million | $12.38 million | $6.04 million |
| General and administrative | $1.34 million | $0.63 million | $2.52 million | $1.27 million |
| Net loss | $7.99 million | $3.60 million | $14.22 million | $6.80 million |
| Operating cash used | Not separately stated | Not separately stated | $12.58 million | $5.68 million |
- At June 30, cash and cash equivalents were $50.25 million, current assets $51.44 million, current liabilities $4.83 million, total liabilities $5.34 million, and accumulated deficit $39.95 million. No variable-rate debt was outstanding; debt balances are not presented as a significant funding source.
- Six-month financing cash flow was $25.77 million, including $24.79 million net proceeds from the second Series B preferred-stock tranche and proceeds from warrant and option exercises. Cash increased $13.15 million during the period.
- After quarter-end, the August 3 IPO raised $120.3 million net of underwriting discounts and commissions but before estimated offering costs. The filing elsewhere reports approximately $118.3 million net after estimated offering expenses; see verification items below. Preferred stock converted to Class A common stock upon the IPO.
Material changes versus prior comparable periods
- Q2 revenue grew 37%; six-month revenue grew 46%, from computational biology services. Management expects service revenue to remain similar near term but says it may decline as the company prioritizes its own pipeline.
- Operating expenses rose sharply: Q2 R&D increased 117% and G&A 113%; six-month R&D increased 105% and G&A 98%. Management attributed much of the R&D growth to external preclinical research and increased discovery and later-stage preclinical work, as well as higher headcount.
- Six-month net loss more than doubled year over year. Gross margin was slightly higher in Q2 but lower for the six-month period.
Outlook, risks, and unusual items
- Management expects continued losses and higher R&D, G&A, and capital spending. It estimates cash, including IPO proceeds, will fund operations into 2024, but cautions that assumptions may prove wrong and capital could be used faster.
- The lead candidate IMM-1-104 was in IND-enabling studies. The company planned to submit an IND in Q1 2022 and, if accepted, initiate a Phase 1 trial in the first half of 2022. It anticipated at least two further oncology INDs, one each in 2023 and 2024.
- Key risks include clinical, regulatory, safety, manufacturing, financing, intellectual-property, third-party-provider, competition, and COVID-19-related uncertainty. The company relies on outside contractors and had no approved products or product-sales revenue.
- A company officer served on the board of a CRO that provided services; the CRO received $2.10 million in R&D-related payments or costs for the six months, and $352,642 was owed at June 30. The filing states it was not aware of material legal matters.
- Management said disclosure controls were effective as of June 30, 2021, and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Reconcile the IPO proceeds: the notes and MD&A cite approximately $120.3 million net before offering costs, while the use-of-proceeds section cites approximately $118.3 million after estimated costs. The filing also inconsistently describes the underwriters’ option as 1.125 million versus 1.150 million shares in one MD&A passage; the IPO note and cover describe 1.125 million.
- Track IMM-1-104 IND submission and trial-start timing, and the progress and funding needs of other pipeline programs.
- Monitor cash burn against the stated runway into 2024, particularly as research spending and public-company costs increase.
- Assess the service-revenue decline risk and the CRO relationship, including related-party spending and amounts payable.
- Review dilution from IPO shares, preferred-stock conversion, outstanding options, and the new equity incentive and employee stock purchase plans.